- Home
- RAVE vs ALGS Comparison
RAVE vs ALGS Comparison
Compare RAVE & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAVE | ALGS |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 40.6M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RAVE | ALGS |
|---|---|---|
| Price | $2.44 | $8.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 40.1K | 37.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 88.30 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,120,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $4.20 |
| 52 Week High | $3.75 | $13.69 |
Technical Indicators
Market Signals| Indicator | RAVE | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 65.07 |
| Support Level | $2.28 | $6.25 |
| Resistance Level | $3.21 | $8.90 |
| Average True Range (ATR) | 0.18 | 0.64 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 29.38 | 87.82 |
Price Performance
Historical ComparisonAbout RAVE Rave Restaurant Group Inc.
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.